For molecular subtypes, data of 1,538 of these patients were missing, 26.56% (1,088), 34.55% (1,415) and 15.38% (630) were lumina A, lumina B and HER-2 amplified breast cancer carriers, respectively, and 23.51% (963) were diagnosed with basal-like breast cancer. This evidence concerns the gene ERBB2 and breast cancer.